SwipeRx is proud to share the impact we have made throughout the year with the release of the SwipeRx Annual Impact Report, developed in collaboration with our investor and partner
SwipeRx is proud to share the impact we have made throughout the year with the release of the SwipeRx Annual Impact Report, developed in collaboration with our investor and partner MDI Ventures. MDI, backed by Telkom Indonesia, is Indonesia’s largest
As the COVID-19 pandemic continues, a significant strain is felt globally on healthcare systems. With more hospitals overloaded, and rural communities underserved, the public is
mClinica Pharmacy Solutions has conducted a survey on SwipeRx platform and revealed insights and actions required by pharmaceutical companies, governments and local communities that are
While many industries are able to continue working from home, there’s one industry that can’t – the healthcare industry. The pharmacy network, healthcare clinics and
On the 5th March 2020 at Serai Restaurant, Paradigm Mall in Malaysia, representatives from mClinica Pharmacy Solutions, a leading healthtech provider, and Persatuan Penolong Pegawai
On 4 March 2020, Japanese firm Takeda Pharmaceutical Co announced they are working on a plasma-derived therapy to treat high-risk patients infected with COVID-19. They
The US Food and Drug Administration (FDA) released a statement on 13 September 2019 to alert patients and healthcare professionals of possible contamination of N-Nitrosodimethylamine
As of 26 February, infections of coronavirus have been detected in 28 countries outside of China – 11 of them are Asian countries and some reports have
The coronavirus has taken the world by storm. As of 23 Feb 2020, the global COVID-19 case count stands at over 78,800 confirmed cases with a death toll of over 2,400.
What is COVID-19? COVID-19, formerly known as the 2019 novelcoronavirus (nCov-19) and, the Wuhan coronavirus, is an upper respiratory tract illness that has flu-like symptoms. These include a
© 2024 mClinica Pte. Ltd. All Rights Reserved.